Income Tax Expense (Benefit) of Apogee Therapeutics, Inc. from 31 Mar 2022 to 30 Sep 2025

Taxonomy & unit: us-gaap: USD
Description: Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary: Apogee Therapeutics, Inc. quarterly and annual Income Tax Expense (Benefit) in USD history and change rate from 31 Mar 2022 to 30 Sep 2025.
Apogee Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending 30 Sep 2025 was $61,000.
Apogee Therapeutics, Inc. Income Tax Expense (Benefit) for the twelve months ending 30 Sep 2025 was $234,000.
Apogee Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2024 was $18,000.
Source SEC data: View on sec.gov

Income Tax Expense (Benefit), Trailing 12 Months (USD)

Income Tax Expense (Benefit), Quarterly (USD)

Income Tax Expense (Benefit), Annual (USD)

Apogee Therapeutics, Inc. Quarterly Income Tax Expense (Benefit) (USD)

Period	TTM Value	Value	YoY Chg	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
Q3 2025	$234,000	$61,000	+$61,000	01 Jul 2025	30 Sep 2025	10-Q	10 Nov 2025	2025	Q3
Q2 2025	$173,000	$72,000	+$72,000	01 Apr 2025	30 Jun 2025	10-Q	11 Aug 2025	2025	Q2
Q1 2025	$101,000	$83,000	+$83,000	01 Jan 2025	31 Mar 2025	10-Q	12 May 2025	2025	Q1
Q4 2024	$18,000	$18,000		01 Oct 2024	31 Dec 2024	10-K	03 Mar 2025	2024	FY
Q3 2024		$0		01 Jul 2024	30 Sep 2024	10-Q	10 Nov 2025	2025	Q3
Q2 2024		$0		01 Apr 2024	30 Jun 2024	10-Q	11 Aug 2025	2025	Q2
Q1 2024		$0		01 Jan 2024	31 Mar 2024	10-Q	12 May 2025	2025	Q1
Q2 2022		$0		01 Apr 2022	30 Jun 2022	10-Q	28 Aug 2023	2023	Q2
Q1 2022		$0		01 Mar 2022	31 Mar 2022	10-Q	28 Aug 2023	2023	Q2

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
2024	$18,000	+$18,000		01 Jan 2024	31 Dec 2024	10-K	03 Mar 2025	2024	FY
2023	$0			01 Jan 2023	31 Dec 2023	10-K	05 Mar 2024	2023	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.